Prognostic importance of primary tumor location in RAS mutant metastatic colorectal cancer
Öz
Objective:
The prognostic value of tumor location in patients with metastatic colorectal
cancer (mCRC) was reported by recent analyses in RAS wild-type patients.
However, there is no enough specific data regarding prognostic value of primary
tumor location in RAS mutated mCRC patients. We aimed to find if there is any
relation between tumor prognosis and primary tumor location in patients with
RAS mutated mCRC.
Method: This
retrospective study included 57 patients with mCRC who were diagnosed and
treated in our hospital between January 2011 and December 2017. Characteristics
features of the patients were obtained from our institution patient medical
records. Patients were included to the present study if KRAS or NRAS mutation
was detected in tumor tissues.
Results: Twenty-nine
(50.9%) of patients were female and the median age of all patients was 52
(18-80) years. Forty (70.2%) of 57 patients were defined as left side (LS) and
17 (29.8%) of patients were located in the right side (RS). As first line
systemic treatment, twenty-five (43.9%) patients had received oxaliplatin-based
chemotherapy while 32 (56.1%) patients had received irinotecan-based
chemotherapy. Tumor sidedness did not affect on PFS (mPFS, 10.9 months for LS
vs 8.1 months for RS, p=0.400) and OS (mOS, 20.9 months for LS vs 20.8 months
for RS, p=0.930).The patients who had oxaliplatin based chemotherapy regimens
showed better OS rate than irinotecan based regimens (28.7months vs16.3 months,
p=0.017, respectively).
Conclusion: Our study results support the thought that claims the sidedness of primary CRC in metastatic setting does not have effect on PFS and OS in patients with RAS mutant mCRC. However, our findings also underline the necessity of studies with larger patient populations and subgroup analyzes to evaluate potential prognostic and molecular features to determine the standart approach to this specific subgroup of the disease.
Anahtar Kelimeler
Kaynakça
- 1. Ferlay J, Soerjomataram I, Dikshit R, et all. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136: 359–86.
- 2. Guinney J, Dienstmann R, Wang X,et all. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015; 21: 1350–6.
- 3. Auclin E, Zaanan A, Vernerey D,et all. Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy. Ann Oncol Off JEur Soc Med Oncol. 2017; 28: 958–68.
- 4. Lie`vre A, Bachet J-B, Boige V, et all. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol Off J Am Soc Clin Oncol. 2008; 26: 374–9.
- 5. Rothberg PG, Spandorfer JM, Erisman MD, et all. Evidence that c-myc expression defines two genetically distinct forms of colorectal adenocarcinoma. Br J Cancer. 1985; 52: 629–32.
- 6. Meza R, Jeon J, Renehan AG, Luebeck EG. Colorectal cancer incidence trends in the United States and United Kingdom: evidence of right- to left-sided biological gradients with implications for screening. Cancer Res 2010; 70: 5419–29.
- 7. Van Cutsem E, Cervantes A, Adam R et all. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016; 27: 1386–1422.
- 8. Venook AP, Niedzwiecki D, Innocenti F, et al. Impact of primary (1°) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol. 2016; 34: 3504.
Ayrıntılar
Birincil Dil
İngilizce
Konular
Sağlık Kurumları Yönetimi
Bölüm
Araştırma Makalesi
Yazarlar
Muhammet Ali Kaplan
Bu kişi benim
0000-0003-0882-0524
Mehmet Küçüköner
Bu kişi benim
0000-0001-7336-871X
Zuhat Urakçı
Bu kişi benim
0000-0003-3878-988X
Yasin Sezgin
Bu kişi benim
0000-0003-4122-8389
Senar Ebinç
Bu kişi benim
0000-0002-0878-6525
Erkan Bilen
Bu kişi benim
0000-0002-7643-4054
Oğur Karhan
Bu kişi benim
0000-0002-7140-8957
Şahin Laçin
Bu kişi benim
0000-0002-8770-9842
Hüseyin Büyükbayram
Bu kişi benim
0000-0002-7168-1507
Abdurrahman Işıkdoğan
Bu kişi benim
0000-0002-7451-7286
Yayımlanma Tarihi
11 Haziran 2019
Gönderilme Tarihi
11 Ocak 2019
Kabul Tarihi
4 Mart 2019
Yayımlandığı Sayı
Yıl 2019 Cilt: 46 Sayı: 2